Inhibition of NEAT1 for treatment of solid tumors

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO RE48856
SERIAL NO

16598873

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
KATHOLIEKE UNIVERSITEIT LEUVEN K U LEUVEN R&D3000 LEUVEN
VIB VZW9052 GENT

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Marine, Jean-Christophe Linden, BE 13 65
Standaert, Laura Zottegem, BE 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 21, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 21, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 21, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00